Legacy Private Trust Co. acquired a new position in Zoetis Inc (NYSE:ZTS) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 4,796 shares of the company’s stock, valued at approximately $544,000.
Several other institutional investors have also added to or reduced their stakes in ZTS. Dimensional Fund Advisors LP boosted its holdings in Zoetis by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,425,455 shares of the company’s stock valued at $121,929,000 after purchasing an additional 39,319 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Zoetis by 14.4% during the 4th quarter. Geode Capital Management LLC now owns 6,227,976 shares of the company’s stock worth $531,801,000 after acquiring an additional 785,088 shares in the last quarter. Advisory Services Network LLC boosted its stake in shares of Zoetis by 8.3% during the 4th quarter. Advisory Services Network LLC now owns 4,490 shares of the company’s stock worth $383,000 after acquiring an additional 344 shares in the last quarter. Actinver Wealth Management Inc. purchased a new stake in shares of Zoetis during the 4th quarter worth about $218,000. Finally, Sowell Financial Services LLC boosted its stake in shares of Zoetis by 7.5% during the 4th quarter. Sowell Financial Services LLC now owns 5,064 shares of the company’s stock worth $433,000 after acquiring an additional 352 shares in the last quarter. Institutional investors and hedge funds own 90.11% of the company’s stock.
Several equities research analysts have recently issued reports on the stock. Barclays reissued a “hold” rating on shares of Bank of Montreal in a research note on Tuesday, June 11th. Stifel Nicolaus lowered shares of Viveve Medical from a “buy” rating to a “hold” rating and lowered their target price for the stock from $3.00 to $1.00 in a research note on Monday, July 22nd. Craig Hallum increased their target price on shares of Zoetis from $114.00 to $132.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Credit Suisse Group lowered their target price on shares of Diplomat Pharmacy from $10.00 to $8.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 target price (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $111.73.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.09. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter in the prior year, the firm earned $0.75 EPS. The company’s revenue for the quarter was up 6.5% on a year-over-year basis. As a group, sell-side analysts expect that Zoetis Inc will post 3.48 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 19th will be given a dividend of $0.164 per share. The ex-dividend date is Thursday, July 18th. This represents a $0.66 annualized dividend and a dividend yield of 0.57%. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.
In other Zoetis news, insider Clinton A. Jr. Lewis sold 6,123 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $113.09, for a total value of $692,450.07. Following the completion of the sale, the insider now owns 46,812 shares in the company, valued at approximately $5,293,969.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,900 shares of the stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $110.58, for a total transaction of $210,102.00. Following the completion of the sale, the director now owns 2,816 shares of the company’s stock, valued at approximately $311,393.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 76,613 shares of company stock valued at $7,963,366. Insiders own 0.29% of the company’s stock.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
See Also: What is the return on assets formula?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.